Bristol-Myers Squibb Company with ticker code (BMY) now have 20 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between $78.56 and $37.89 and has a mean share price target at $52.26. (at the time of writing). Now with the previous closing price of $51.33 and the analysts are correct then there would likely be a percentage uptick in value of 1.8%. The 50 day MA is $50.41 and the 200 moving average now moves to $57.32. The market capitalization for the company is 104.50B. The stock price for the company is currently $51.68 USD
The potential market cap would be $106,389,937,204 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 13.39, revenue per share of $21.75 and a 5.63% return on assets.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
